Evidence map›Paper›PMID 39173604›Full record

Observational studyAmerican journal of nephrology2024

The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.

Carol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, Richard Ofori-Asenso, Ewelina Palmer, Anna Niklasson, Andrew Linder, Helen Woodward, Surendra Pentakota, Juan Jose Garcia Sanchez and 4 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in American journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04034992 (An Observational Study Collecting Real-world Data on Patients With Chronic Kidney Disease to Assess), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04034992 completednot on this map

An Observational Study Collecting Real-world Data on Patients With Chronic Kidney Disease to Assess: Early Treatment Experience, Treatment Patterns, Treatment Effectiveness, Patient Outcomes and Patient Quality of Life Through Prospective and Retrospective Data Capture

TypeobservationalSponsorAstraZenecaRan2019 to 2023Enrolled1,052ConditionsChronic Kidney Disease
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carol PollockKolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Juan-Jesus CarreroDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
Eiichiro KandaDepartment of Health Data Science, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Richard Ofori-AsensoCardiovascular, Renal, Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Ewelina PalmerPatient Centered Science, AstraZeneca, Cambridge, UK.
Anna NiklassonPatient Centered Science, AstraZeneca, Gothenburg, Sweden.
Andrew LinderCalibrations Counseling & Consultation, Akron, Ohio, USA.
Helen WoodwardKidney Research UK, Peterborough, UK.
Surendra PentakotaGlobal Medical Affairs, Biopharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Juan Jose Garcia SanchezGlobal Market Access and Pricing, AstraZeneca, Barcelona, Spain.
Naoki KashiharaDepartment of Health Data Science, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Steven FishbaneDivision of Nephrology, Zucker School of Medicine, Great Neck, New York, USA.
Roberto Pecoits-FilhoSchool of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil.
David C WheelerDepartment of Renal Medicine, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) can have a profound impact on patients' lives. However, multinational data on patients' lived experience with CKD are scarce.

methodsIndividuals from the prospective cohort of DISCOVER CKD (NCT04034992), an observational cohort study, were recruited to participate in one-to-one telephone interviews to explore their lived experience with CKD. A target of 100 participant interviews was planned across four countries (Japan, Spain, the UK, and the USA). These qualitative interviews, lasting ∼60-90 min, were conducted in the local language by trained interviewers with specific experience in CKD, between January and June 2023. Transcribed interviews were translated into English for coding and analysis. Data were coded using qualitative research software.

resultsOf the 105 participants interviewed, 103 were included in the final analysis. The average time since CKD diagnosis was 9.5 years, and at least half (50.5%) of participants had CKD stage 3A or 3B. CKD diagnosis was an emotional experience, driven by worry (n = 29/103; 28.2%) and shock (n = 26/103; 25.2%), and participants often reported feeling inadequately informed. Additional information was frequently sought, either online or via other healthcare providers. The proportion of participants reporting no impacts of CKD on their lives was highest in those with CKD stage 1 and 2 (64.3%). Conversely, every participant in the CKD stage 5 on dialysis group reported some impact of CKD on their lives. Across all participants, the most reported impacts were anxiety or depression (37.9%) or ability to sleep (37.9%). The frequency of the reported impacts appeared to increase with disease severity, with the highest rates observed in the dialysis group. In that group, the most frequently reported impact was on the ability to work (80.0%).

conclusionFindings from this multinational qualitative study suggest that patients may experience symptoms and signs of disease prior to diagnosis; however, these are often nonspecific and may not be directly associated with CKD. Once diagnosed, the burden of CKD can have a diverse, negative impact on various aspects of patients' lives. This highlights the need for early identification of at-risk individuals, and the importance of early CKD diagnosis and management with guideline-directed therapies to either prevent further deterioration of CKD or slow its progression, thus reducing symptom burden and improving quality of life.

Indexed as

Renal Insufficiency, ChronicAdultAgedCohort StudiesFemaleHumansInterviews as TopicMaleMiddle AgedProspective StudiesQualitative ResearchQuality of LifeSpainUnited StatesChronic kidney diseaseDISCOVER CKDPatient experiencePatient insightsTelephone interview

Identifiers

PMID39173604
PMCPMC11651223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.